Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

56.67
+0.34000.60%
Post-market: 56.670.00000.00%19:15 EDT
Volume:2.00M
Turnover:114.07M
Market Cap:7.93B
PE:38.42
High:58.64
Open:57.16
Low:56.24
Close:56.33
52wk High:76.76
52wk Low:9.57
Shares:140.01M
Float Shares:120.00M
Volume Ratio:0.70
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.48
EPS(LYR):-0.0122
ROE:75.50%
ROA:14.35%
PB:13.96
PE(LYR):-4,647.75

Loading ...

Arrowhead Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
Dec 11, 2025

RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Dec 11, 2025

Arrowhead Pharmaceuticals Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Dec 11, 2025

Director Michael S. Perry Reports Sale of Arrowhead Pharmaceuticals Common Shares

Reuters
·
Dec 10, 2025

Arrowhead Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Dec 10, 2025

U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico

Reuters
·
Dec 09, 2025

Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease

Reuters
·
Dec 08, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Mapt for the Treatment of Alzheimer’s Disease and Other Tauopathies

THOMSON REUTERS
·
Dec 08, 2025

Arrowhead Pharmaceuticals Unveils Pipeline Progress and First Commercial Launch in Investor Presentation

Reuters
·
Dec 08, 2025

Stock Track | Arrowhead Pharmaceuticals Soars 5.01% on FDA Breakthrough Therapy Designation for Plozasiran

Stock Track
·
Dec 03, 2025

Arrowhead Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia Drug

Dow Jones
·
Dec 02, 2025

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

THOMSON REUTERS
·
Dec 02, 2025

Arrowhead Pharmaceuticals: Intends to Submit a Supplemental New Drug Application (Snda) to FDA by Year-End 2026

THOMSON REUTERS
·
Dec 02, 2025

Arrowhead Pharmaceuticals - to Complete Phase 3 Studies by Mid-2026

THOMSON REUTERS
·
Dec 02, 2025

Arrowhead Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $85 From $80

THOMSON REUTERS
·
Dec 02, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Simply Wall St.
·
Dec 02, 2025

Arrowhead Pharmaceuticals Director Mauro Ferrari Reports Sale of Common Shares

Reuters
·
Dec 02, 2025

Stock Track | Arrowhead Pharmaceuticals Soars 8.61% Intraday on FDA Approval of First siRNA Therapy for FCS

Stock Track
·
Dec 02, 2025

Stock Track | Arrowhead Pharmaceuticals Soars 8.61% Intraday on FDA Approval of First siRNA Therapy

Stock Track
·
Dec 02, 2025

Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday on FDA Approval of First siRNA Therapy for FCS

Stock Track
·
Dec 01, 2025